Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous dendritic cell vaccine with radiotherapy and/or interferon alfa in metastatic melanoma
2012-001410-41Phase 2Completed
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Jul 2012
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of interferon alfa-2b and aldesleukin in melanoma (4 arms), sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Primary endpoints: Immune-related disease control rate and Immunological activity. Started Jul 2012; status: completed.
02
Drugs
interferon alfa-2baldesleukin
03
Conditions
melanoma
Beyond the preview
Go deeper on 2012-001410-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001410-41.